Close Menu

Originally published July 29.

NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved an expanded indication for the leukemia drug Imbruvica (ibrutinib) as a treatment for chronic lymphocytic leukemia patients who harbor a deletion in chromosome 17.

According to Samina Bari, a spokesperson for drug sponsor Pharmacyclics, Imbruvica is the first FDA-approved drug for CLL patients with 17p deletions, a subset in which there is high unmet need in terms of viable treatments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.